Literature DB >> 1499546

Inhibition of calcium-dependent release of noradrenaline from PC12 cells by botulinum type-A neurotoxin. Long-term effects of the neurotoxin on intact cells.

C C Shone1, J Melling.   

Abstract

(a) Clostridium botulinum type-A neurotoxin (BoNTA) inhibited the calcium-dependent release of noradrenaline from PC12 cells in a dose-dependent manner. Under conditions in which intact PC12 cells were incubated with BoNTA for 20 h at 37 degrees C, a neurotoxin concentration of approximately 0.12 +/- 0.03 microM was required to inhibit 50% of the calcium-dependent noradrenaline release. (b) PC12 cells, differentiated in the presence of nerve growth factor for 14 days, showed a similar dose-dependent inhibition of noradrenaline release by BoNTA with unchanged sensitivity. No specific saturable binding of 125I-labelled BoNTA was observed to either differentiated or undifferentiated PC12 cells, suggesting a lack of high-affinity acceptors on the cell surface for the neurotoxin. It is proposed that BoNTA enters PC12 cells either by non-specific binding to the cell membrane or via a low-concentration low-affinity acceptor molecule. (c) A study of the long-term effects of BoNTA on noradrenaline release from PC12 cells showed that the neurotoxin remains active within the growing cells for several days. Noradrenaline release from PC12 cells exposed to BoNTA (0.3 microM) for 24 h was reduced to less than 20% of control values over a subsequent 4-day period. After 8 days, release levels were significantly lower (60-65%) than control values, despite a more than 10-fold increase in the cell mass. (d) Investigation of the subcellular distribution of BoNTA after incubation with PC12 cells for 96 h revealed the bulk of the toxin (94-98%) to be associated with the cell membrane fraction. Of this, 50-80% of the BoNTA was associated with the nuclear and cell debris fraction and 11-25% was recovered in the large-granule-vesicle fraction; the specific binding of the neurotoxin to these membrane fractions was found to be similar. (e) Examination of the form of the cell-associated BoNTA after incubation for 96 h with PC12 cells revealed no evidence of any significant degradation of either neurotoxin subunit. This suggests that the neurotoxin adopts a relatively stable form within the cell. On SDS/PAGE under non-reducing conditions, no trace of protein bands corresponding to either of the BoNTA subunits were observed, suggesting that little or none of the neurotoxin subunits exists in a monomeric form within the cells.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1499546     DOI: 10.1111/j.1432-1033.1992.tb17137.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  10 in total

1.  [Pharmacology of botulinum toxin drugs].

Authors:  D Dressler
Journal:  HNO       Date:  2012-06       Impact factor: 1.284

Review 2.  [Pharmacological aspects of therapeutic botulinum toxin preparations].

Authors:  D Dressler
Journal:  Nervenarzt       Date:  2006-08       Impact factor: 1.214

3.  Development of novel assays for botulinum type A and B neurotoxins based on their endopeptidase activities.

Authors:  B Hallis; B A James; C C Shone
Journal:  J Clin Microbiol       Date:  1996-08       Impact factor: 5.948

Review 4.  Progress in cell based assays for botulinum neurotoxin detection.

Authors:  Sabine Pellett
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

Review 5.  Botulinum toxins--cause of botulism and systemic diseases?

Authors:  H Böhnel; F Gessler
Journal:  Vet Res Commun       Date:  2005-05       Impact factor: 2.459

6.  Botulinum Toxin: Non-cosmetic Indications and Possible Mechanisms of Action.

Authors:  Uwe Wollina
Journal:  J Cutan Aesthet Surg       Date:  2008-01

7.  Model for studying Clostridium botulinum neurotoxin using differentiated motor neuron-like NG108-15 cells.

Authors:  Regina C M Whitemarsh; Christina L Pier; William H Tepp; Sabine Pellett; Eric A Johnson
Journal:  Biochem Biophys Res Commun       Date:  2012-09-20       Impact factor: 3.575

8.  Botulinum toxin a inhibits acetylcholine release from cultured neurons in vitro.

Authors:  P Ray
Journal:  In Vitro Cell Dev Biol Anim       Date:  1993-06       Impact factor: 2.416

9.  The mechanism of botulinum A on Raynaud syndrome.

Authors:  Yanwen Zhou; Ying Liu; Yunhua Hao; Ya Feng; Lizhen Pan; Wuchao Liu; Bing Li; Libin Xiao; Lingjing Jin; Zhiyu Nie
Journal:  Drug Des Devel Ther       Date:  2018-06-26       Impact factor: 4.162

10.  Stapling of the botulinum type A protease to growth factors and neuropeptides allows selective targeting of neuroendocrine cells.

Authors:  Jason Arsenault; Enrico Ferrari; Dhevahi Niranjan; Sabine A G Cuijpers; Chunjing Gu; Yvonne Vallis; John O'Brien; Bazbek Davletov
Journal:  J Neurochem       Date:  2013-05-20       Impact factor: 5.372

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.